Can we decrease breakthrough bleeding in patients with endometriosis on norethindrone acetate?

Ozgul Muneyyirci-Delale, Ozgul Muneyyirci‐Delale, Muneyyirci-Delale O, Jalou S, Sanae Jalou, Monzila Rahman, Rahman M, Vijaya Nacharaju, Nacharaju V
International journal of fertility and women's medicine · 2003 · vol. 48(1) , pp. 32–6 · PMID:12643518 · W27370433
article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This study compared breakthrough bleeding in endometriosis patients treated with Lupron-Depot alone, norethindrone acetate after Lupron-Depot, or norethindrone acetate alone, finding the combination regimen had comparable bleeding rates to Lupron-Depot alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To compare the breakthrough bleeding in endometriosis patients treated with Lupron-Depot alone, norethindrone acetate following Lupron-Depot, and norethindrone acetate alone. PATIENTS AND METHODS: 71 women with symptomatic surgically diagnosed endometriosis were retrospectively evaluated for this study. 28 women were treated with 6 doses of 3.75 mg Lupron-Depot every 4 weeks (Group I). 15 women were treated first with Lupron-Depot 3.75 mg every 4 weeks for 3 to 6 doses, followed by 5 mg norethindrone acetate (Group II). 28 patients were treated for 6 months with 5 mg per day norethindrone acetate alone (Group III). Breakthrough bleeding during treatment was scored mild (some spotting), moderate (lighter than patient's normal menstruation), or severe (as much as patient's normal menstruation or heavier). Multiple comparisons were done by ANOVA (SPSS) among three groups. The age of patients was not significantly different between groups 134.9-36.8 years). BMI of the three groups was significantly different 126.6 +/- 5.8, 27.4 +/- 6.4, 23.6 +/- 4.5, respectively). RESULTS: Breakthrough bleeding was reported by 14% of Group I, 20% of Group II, and 68% of Group III. CONCLUSION: Endometriosis patients who were treated with norethindrone acetate following Lupron-Depot had significantly less breakthrough bleeding than those given norethindrone acetate alone, and the incidence was comparable to Lupron-Depot alone.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Oral, Synthetic Endometriosis Leuprolide Norethindrone Norethindrone Uterine Hemorrhage Uterus Adult Analysis of Variance Contraceptives, Oral, Synthetic Drug Therapy, Combination Endometriosis Endometriosis Endometriosis Female Humans Leuprolide Norethindrone Norethindrone Acetate Retrospective Studies

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (16)

Cited by (7)

Source provenance

europepmc
last seen: 2026-09-16T06:11:32.772430+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:55.732728+00:00
License: CC0 · commercial use OK